🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

PharmEasy’s CEO Siddharth Shah steps down; Thyrocare chief Rahul Guha to take over

EntrackrEntrackr · 1m ago
PharmEasy’s CEO Siddharth Shah steps down; Thyrocare chief Rahul Guha to take over
Medial

Siddharth Shah, cofounder and current MD and CEO of API Holdings, the parent company of PharmEasy and Thyrocare, is stepping down from his executive role. He will take on the role of Vice Chairman and Director of the company effective August 27, 2025. Rahul Guha, who currently serves as the MD and CEO of Thyrocare, will take over as the new MD and CEO of API Holdings. The announcement was made through regulatory filings by Thyrocare on Wednesday and is part of a wider leadership transition within the group. Guha will continue to lead Thyrocare alongside his new responsibilities at API. Before this appointment, Guha held the position of President of Operations at API, where he was responsible for overseeing integration and coordination across the group companies. For background, PharmEasy had acquired a majority stake (66.1%) in Thyrocare for Rs 4,546 crore in June 2021. Guha’s appointment reflects API’s focus on consolidating leadership across verticals as the company navigates a difficult funding environment and prepares for a possible public listing. API had filed draft IPO papers in 2021 but later withdrew them due to market conditions. PharmEasy has raised about $1.1 billion from investors including MEMG, Prosus, and Temasek. In April 2024, it secured $216 million at a steep 90% drop in valuation to $710 million. Earlier this year, PharmEasy’s three cofounders Dharmil Sheth, Dhaval Shah, and Hardik Dedhia stepped back from the Bengaluru-based firm. They recently launched their new venture All Home. The company secured an undisclosed investment round led by Bessemer Venture Partners at a valuation of more than $120 million, with Siddharth Shah also participating as an investor.

Related News

PharmEasy reports Rs 5,872 Cr revenue in FY25; burn remains flat

EntrackrEntrackr · 9d ago
PharmEasy reports Rs 5,872 Cr revenue in FY25; burn remains flat
Medial

PharmEasy reports Rs 5,872 Cr revenue in FY25; burn remains flat API Holdings, the parent of e-pharmacy and diagnostics brand PharmEasy, reported flat revenue in the fiscal year ending March 2025. However, the Mumbai-based company has cut losses by 38% due to a sharp reduction in finance and depreciation costs during the last fiscal year. PharmEasy’s operating revenue increased 3.7% to Rs 5,872 crore in FY25 from Rs 5,664 crore in FY24, according to the company’s financial statements reviewed by Entrackr. PharmEasy offers pharmaceutical products, along with diagnostic services and teleconsultations, through its mobile and web apps. PharmEasy derived about 87% of its operating revenue, or Rs 5,097.5 crore, from the sale of pharmaceutical and cosmetic products, while the remainder came from services such as diagnostics, teleconsultations, delivery, warehousing, and commissions from facilitating pathological tests. The firm also earned Rs 108 crore in non-operating income from interest and asset gains, taking its total revenue to Rs 5,898 crore in FY25. On the expenses side, the cost of materials remains the largest cost centre constituting 67.2% of the total expenditure to Rs 4,844 crore in FY25. PharmEasy’s employee benefit expenses went up by 30% to Rs 908.4 crore in the last fiscal year as compared to Rs 700 crore in FY24. Meanwhile, finance costs also went down 30% to Rs 506 crore while the depreciation and amortization expenses declined 21.7% to Rs 168.9 crore during the year. Contractual payment for delivery associates was another significant cost at Rs 90 crore. Other expenses include legal, professional, sales promotion, and marketing. The company’s overall expenses also remained flat at Rs 7,208.5 crore in FY25. While the company’s revenue and expenses remained largely unchanged in FY25, a reduction in exceptional items such as early redemption charges on non-convertible debentures, goodwill impairment and others helped narrow its losses by 38% to Rs 1,572.3 crore compared to Rs 2,533.5 crore in FY24. PharmEasy’s EBITDA (loss) stood at Rs 553.5 crore while its ROCE and EBITDA margin improved marginally to -13.9% and -15.71%, respectively. On a unit level, Pharmeasy spent Rs 1.23 to earn a rupee of revenue during the fiscal year ending March 2025. Thyrocare, a diagnostic and preventive healthcare service provider, in which Pharmeasy acquired a majority stake in June 2021, posted Rs 687.5 crore in FY25, a 20% increase compared to Rs 571.88 crore in FY24. During the same period, its profit also grew by 30% to Rs 90.75 crore. Earlier this year, PharmEasy cofounders Dharmil Sheth, Dhaval Shah, and Hardik Dedhia stepped back from the company, while the fourth cofounder Siddharth Shah exited last month. The parent entity API Holdings has now appointed Rahul Guha, who also serves as the MD and CEO of Thyrocare, as its new MD and CEO. According to the startup data intelligence platform TheKredible, PharmEasy has raised around $1.1 billion to date from Ranjan Pai’s MEMG, Prosus, and Temasek, among others.

PharmEasy raises fresh debt to clear Goldman Sachs loan after 90% valuation cut

EntrackrEntrackr · 1d ago
PharmEasy raises fresh debt to clear Goldman Sachs loan after 90% valuation cut
Medial

PharmEasy raises fresh debt to clear Goldman Sachs loan after 90% valuation cut Mumbai-based healthtech unicorn PharmEasy has raised Rs 1,700 crore ($193 million) in debt funding led by 360 One, with participation from Alkram Ventures, MVS Ventures, Bennett Coleman, and other investors. The debt round is the firm’s third infusion in four years, highlighting its ongoing dependence on high-cost borrowing to service earlier loans. The fresh debt infusion looks to complete repayment of its Goldman Sachs loan, which it had raised in May 2022 for Rs 2,700 crore at a high interest rate to refinance the Rs 2,200 crore Kotak Mahindra Bank loan used to acquire Thyrocare in 2021. The Goldman Sachs’ loan had certain financial conditions tied to the company’s spending, which were breached in June 2023, though PharmEasy has continued to make all payments on time. The 360 One-led debt round involves the allotment of 1,700 non-convertible debentures at Rs 10 lakh each, as per the filings with the Registrar of Companies. 360 One contributed Rs 1,231 crore, while Micro Labs Limited put in Rs 210 crore. MVS Ventures invested Rs 78 crore, with Bennett Coleman and Alkram Ventures contributing Rs 50 crore and Rs 42 crore, respectively. Eight other investors, including Kyrush Investments, Medley Pharmaceuticals, and Mahalaxmi Trust, covered the remaining sum. This fundraising follows a $216 million capital raise in April 2024, which came at a 90% valuation haircut to $710 million from PharmEasy’s $5.6 billion peak in 2021. That round, led by MEMG with participation from Prosus, Temasek, and others, was aimed at shoring up finances amid slowing growth and high debt obligations. Founded in 2019, PharmEasy offers pharmaceutical products, diagnostics, and teleconsultations through its web and mobile platforms. The company has now completed its third circle of debt, highlighting the ongoing challenge of balancing aggressive growth ambitions with high-cost leverage. Over the past two years, the company saw the exit of all co-founders and major changes at the leadership level, with Rahul Guha, MD and CEO of Thyrocare, taking over as MD and CEO of PharmEasy. For FY25, PharmEasy reported flat revenue of Rs 5,872 crore while cutting losses by 38% to Rs 1,572 crore from Rs 2,533 crore in FY24, signaling modest operational improvements even as debt obligations remain a critical focus.

PharmEasy's three co-founders step down, Siddharth Shah to lead

EntrackrEntrackr · 7m ago
PharmEasy's three co-founders step down, Siddharth Shah to lead
Medial

PharmEasy's three co-founders step down, Siddharth Shah to lead Online pharmacy company PharmEasy is undergoing a major transition as three co-founders—Dharmil Sheth, Dhaval Shah, and Hardik Dedhia—have stepped back from the Bengaluru-based firm. The fourth co-founder, Siddharth Shah, will continue to lead the company. According to a company statement, these co-founders will remain part of the group, align their shareholding for the long term, and continue as board members or observers. However, they have expressed their desire to reduce their involvement in active day-to-day executive responsibilities. In November last year, Entrackr approached the co-founders of PharmEasy for confirmation, but they firmly denied the claims. PharmEasy also said that this transition has been in the works for several quarters, adding, "We are delighted that the new team has achieved operational cash flow break-even and continues to handle all responsibilities effectively." “The three of us—Dhaval, Dharmil, and Hardik—are starting something new in the consumer space. Reputed VCs who backed us at PharmEasy are backing us again,” the co-founders said in a joint statement. PharmEasy has raised approximately $1.1 billion to date from investors, including Ranjan Pai’s MEMG, Prosus, and Temasek. In April 2024, the company secured $216 million in funding during a down round, valuing it at around $710 million (post-money). However, in September, global asset management firm Janus Henderson reduced its valuation by 91.8% to $458 million. This development coincides with PharmEasy's efforts to relaunch its initial public offering (IPO). The company initially filed draft papers for an IPO in November 2021 but later withdrew the application, citing adverse market conditions and strategic considerations. PharmEasy’s revenue from operations declined by 14.8% to Rs 5,664 crore in FY24 from Rs 6,644 crore in FY23. Following cost-cutting measures, the company reduced its losses by 51.4% to Rs 2,533.5 crore in the last fiscal year.

Sridhar Vembu steps down as CEO of Zoho Corp

EntrackrEntrackr · 7m ago
Sridhar Vembu steps down as CEO of Zoho Corp
Medial

Sridhar Vembu steps down as CEO of Zoho Corp Shailesh Kumar Davey, co-founder of Zoho, will take over as the new Group CEO, while another co-founder, Tony Thomas, will lead Zoho US. Sridhar Vembu, the founder and CEO of Zoho Corp, has transitioned from his active role to take on a new position as Chief Scientist, where he will focus on driving deep R&D initiatives. “In view of the various challenges and opportunities facing us, including recent major developments in AI, it has been decided that it is best that I should focus full time on R&D initiatives, along with pursuing my personal rural development mission,” said Vembu. Shailesh Kumar Davey, co-founder of Zoho, will take over as the new Group CEO, while another co-founder, Tony Thomas, will lead Zoho US. Rajesh Ganesan will head the ManageEngine division, and Mani Vembu will oversee the Zoho.com division. “The future of our company entirely depends on how well we navigate the R&D challenge, and I am looking forward to my new assignment with energy and vigor. I am also very happy to get back to hands-on technical work,” added Vembu. Zoho is one of India’s largest profit-generating SaaS companies, reporting a profit of Rs 2,836 crore in FY23, with revenue growing 29.7% to Rs 8,703.6 crore during the fiscal year. The company has yet to file its annual report for FY24.

Download the medial app to read full posts, comements and news.